Jazz Pharmaceuticals Highlights Zanidatamab and Zepzelca Cancer Trials at ESMO Congress
Jazz Pharmaceuticals Highlights Zanidatamab and Zepzelca Cancer Trials at ESMO Congress
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced that the Company, along with its partners, will present five abstracts at the European Society for Medical Oncology (ESMO) Congress 2024 from September 13-17, 2024, in Barcelona, Spain. Presentations include data from trials of zanidatamab and Zepzelca (lurbinectedin).
爵士製藥有限公司（納斯達克股票代碼：JAZZ）今天宣佈，該公司及其合作伙伴將在2024年9月13日至17日在西班牙巴塞羅那舉行的2024年歐洲腫瘤內科學會（ESMO）大會上提交五份摘要。演示文稿包括來自zanidatamab和Zepzelca（lurbinectedin）試驗的數據。
New and updated data with longer follow-up, including overall survival findings, will be presented from an ongoing Phase 2 trial of zanidatamab, an investigational dual HER2-targeted bispecific antibody, in combination with chemotherapy for the first-line treatment of HER2-positive metastatic gastroesophageal adenocarcinoma (mGEA). Additional data from a Phase 2 study evaluating zanidatamab in combination with chemotherapy and bevacizumab as first-line treatment in HER2-positive metastatic colorectal cancer demonstrating encouraging antitumor activity will be presented as a mini-oral presentation at the congress.
正在進行的zanidatamab（一種雙靶向HER2雙特異性抗體）與化療聯合用於HER2陽性轉移性胃食管腺癌（mGeA）一線治療的化療的2期臨床試驗將提供具有更長隨訪時間的新數據和更新的數據，包括總體存活率。一項評估zanidatamab聯合化療和貝伐珠單抗作爲HER2陽性轉移性結直腸癌的一線治療的2期研究的其他數據將在大會上以小型口頭報告形式公佈，該研究顯示出令人鼓舞的抗腫瘤活性。
譯文內容由第三人軟體翻譯。